1. Kantar Health Expands Emerging Markets Presence with Evidências in Brazil
Who Is Evidências?
Evidências, a Kantar Health company, is an
industry leader in evidence-based, health
management services in Brazil. Evidências
works with all segments of the Brazilian
healthcare market, including health insurers,
government bodies, hospitals, providers,
and pharmaceutical and medical device
manufacturers. With 15 years of evidence-
based medicine (EBM) and healthcare
decision-making expertise, Evidências has
a wide variety of offers such as courses and
training, analysis of highly complex cases in
health, technical support and legal advice for
health technologies, construction of protocols
and clinical guidelines, audits of medical bills
in oncology, dossiers for drug registration and
incorporation of health technologies, consulting
for specialty societies, economic studies and
pharmacoeconomics projects.
Combined Expertise Presents Extended
Capabilities
Kantar Health’s acquisition of Evidências
expands our client’s ability to leverage local
Brazilian experts when conducting clinical
and real-world research. Kantar Health has
gained capabilities in cost-effectiveness
and budget-impact economic models, local
dossier submission packages and professional
writing. Furthermore, Kantar Health also
receives valuable expertise in the DATASUS
governmental database and a key private
insurance EMR database covering 20% of the
privately insured population in Brazil – offering
a complete picture of the healthcare sector in
the country.
Evidências has gained access to Kantar
Health’s leading data assets and global
consulting capabilities, thus strengthening work
in EBM and extending its range of services in
consulting, market access and training.
Clients interested in Brazil can leverage new
opportunities to learn through Evidências
expertise:
„„ Unparalleled access to new sources of
healthcare information
„„ Enhanced scientific expertise
„„ Healthcare economics modeling
„„ Clinical studies and chart studies
„„ Market access
With a diverse group of physicians, including
oncologists, geriatricians, pediatricians and
surgeons, plus nurses, pharmacists and more,
Evidências offers extensive capabilities over a
wide range of therapeutic areas. Capabilities
include issues relation to health plans,
health economics and outcomes research,
scientific communication and courses. The
team evaluates over 14,000 claims per
year, including over 4,000 oncology patients
which make up the exclusive unique private
insurance EMR database. This breadth
of expertise enable systematic literature
reviews, economic models (budget impact and
cost effectiveness), dossiers and thorough
capabilities in health issues related to Brazil
and broader LatAm and the oncology tumor
areas.
Australia
© 2015 Kantar Health www.kantarhealth.com
Kantar Health’s
acquisition of
Evidências expands
our client’s ability to
leverage Brazilian
experts when
conducting clinical
and real-world
research.
Contact Us: For more information, contact us at info@kantarhealth.com or visit
http://www.evidencias.com.br/.

2. www.kantarhealth.com
Partnering with Kantar Health
Kantar Health is a global healthcare
consulting firm and trusted advisor to the
world’s leading pharmaceutical, biotech
and medical device/diagnostic companies.
The firm combines evidence-based
research with deep scientific, therapeutic
and clinical knowledge, commercial
development know-how, and brand and
marketing expertise. To learn more about
our research capabilities in Brazil, contact
us at info@kantarhealth.com, or visit our
website at www.kantarhealth.com.
Australia
Kantar Health and Evidências have a proven track record of client success in Brazil, as evidenced by a breadth of
publications.
Targeted therapy in triple-negative metastatic breast cancer: a systematic review
and meta-analysis. Clark O, Botrel TE, Paladini L, Ferreira MB. Core Evid. 2014
Jan 6;9:1-11.
Decision tree construction and cost-effectiveness analysis of treatment of
ulcerative colitis with pentasa® mesalazine 2 g sachet. Nishikawa AM, Paladini
L, Delfini R, Kotze PG, Clark O. Arq Gastroenterol. 2013 Oct-Dec;50(4):297-303.
Intermittent versus continuous androgen deprivation for locally advanced,
recurrent or metastatic prostate cancer: a systematic review and meta-analysis.
Botrel TE, Clark O, dos Reis RB, Pompeo AC, Ferreira U, Sadi MV, Bretas FF.
BMC Urol. 2014 Jan 25;14:9. doi: 10.1186/1471-2490-14-9.
Budgetary impact of oral chemotherapy incorporation in Brazil: a real world data
analysis from the private payer perspective. Clark O, Alves AFv, Castro AP,
Santos Fb, Faleiros E, Clark L, et al. J Bras Econ Saude. 2013;5(1):10-4.
Systematic review and meta-analysis of target therapies for the treatment of
metastatic renal cancer. Durán M, Matheus W, Ferreira U, Clark O. Int Braz J
Urol. 2013 Nov-Dec;39(6):768-78.
Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the
treatment of HER-2-overexpressing locally advanced or metastatic breast cancer:
systematic review and meta-analysis. Botrel TE, Paladini L, Clark OA. Core
Evid. 2013;8:69-78.
Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific
evidence regarding clinical impact, diagnosis, and treatment. Silva Filho LV,
Ferreira Fde A, Reis FJ, Britto MC, Levy CE, Clark O, Ribeiro JD. J Bras
Pneumol. 2013 Jun-Aug;39(4):495-512.
Hypofractionated external-beam radiation therapy (HEBRT) versus conventional
external-beam radiation (CEBRT) in patients with localized prostate cancer: a
systematic review and meta-analysis. Botrel TE, Clark O, Pompeo AC, Bretas
FF, Sadi MV, Ferreira U, Dos Reis RB. Core Evid. 2013;8:1-13. doi: 10.2147/
CE.S41178. Epub 2013 Mar 7.
Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic
castration-refractory prostate cancer (mCRPC): a systematic review and meta-
analysis. Botrel TE, Clark O, Pompeo AC, Bretas FF, Sadi MV, Ferreira U, Reis
RB. Int Braz J Urol. 2012 Nov-Dec;38(6):717-27. Review.
Goserelin versus leuprolide in the chemical castration of patients with prostate
cancer. Dias Silva É, Ferreira U, Matheus W, Faria EF, Silva GD, Saito M, de
Souza AA, Laranjo A Jr, Clark O, Magna LA, Castilho LN, Reis LO. Int Urol
Nephrol. 2012 Aug;44(4):1039-44.
Ideal vial size for bortezomib: real-world data on waste and cost reduction in
treatment of multiple myeloma in Brazil. Clark L, Castro AP, Fortes AF, Santos
F, Clark O, Engel T, Pegoretti B, Teich V, Vianna D, Puty F. Value Health. 2011
Jul-Aug;14(5 Suppl 1):S82-4. doi: 10.1016/j.jval.2011.05.013.
Antibiotic prophylaxis for transrectal prostate biopsy. Zani EL, Clark
OA, Rodrigues Netto N Jr. Cochrane Database Syst Rev. 2011 May
11;(5):CD006576.
Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone
in previously untreated locally advanced or metastatic non-small cell lung cancer
(NSCLC): systematic review and meta-analysis. Botrel TE, Clark O, Clark L,
Paladini L, Faleiros E, Pegoretti B. Lung Cancer. 2011 Oct;74(1):89-97.
Cost of the treatment of myelodisplastic syndrome in Brazil. Clark O, Faleiros EJ.
Rev Bras Hematol Hemoter. 2011;33(1):31-4.
El Khoury AC, Vietri J, Prajapati G. Health-related quality of life in patients with
hepatitis C virus infection in Brazil. Rev Panam Salud Publica. 2014; 35(3):200-6.
Goren A, Gross HJ, Fujii RK, Pandey A, Mould-Quevedo J. Prevalence of pain
awareness, treatment, and associated health outcomes across different conditions
in Brazil. Rev Dor. 2012; 13: 308-319.
Fujii RK, Goren A, Annunziata K, Mould-Quevedo J. Prevalence, awareness,
treatment, and burden of major depressive disorder: Estimates from the National
Health and Wellness Survey. Value in Health Regional Issues. 2012; 1: 235-243.
Goren A, Roberts C, Victor TW. Comorbid risk, respondent characteristics
and likelihood of pneumococcal vaccination versus no vaccination among
older adults in Brazil. Expert Rev Vaccines. 2014 Jan;13(1):175-84. doi:
10.1586/14760584.2014.863714.